Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 19
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 901 | EXXONMOBIL TECHNOLOGY AND ENGINEERING | 17 | 00% | 1 | 16 | 2022–2026 |
| 902 | FERRING | 17 | 00% | 1 | 16 | 2022–2026 |
| 903 | HALDOR TOPS E A S | 17 | 1270.6% | 1 | 4 | 2019–2022 |
| 904 | HAVER BOECKER OHG | 17 | 15.9% | 0 | 16 | 2021–2025 |
| 905 | HYPERLOOP TECHNOLOGIES | 17 | 00% | 17 | 0 | 2022–2022 |
| 906 | ISEKI | 17 | 00% | 0 | 17 | 2022–2026 |
| 907 | MEDIATEK SINGAPORE | 17 | 00% | 1 | 16 | 2022–2025 |
| 908 | MITSUBISHI TANABE PHARMA | 17 | 15.9% | 3 | 13 | 2022–2025 |
| 909 | NIPPON SEIKI | 17 | 00% | 0 | 17 | 2023–2025 |
| 910 | NIPPON STEEL ENGINEERING | 17 | 741.2% | 0 | 10 | 2022–2025 |
| 911 | PICANOL | 17 | 211.8% | 0 | 15 | 2022–2025 |
| 912 | PILLAI UNIVERSAL | 17 | 1058.8% | 0 | 7 | 2020–2023 |
| 913 | POWER INTEGRATIONS | 17 | 15.9% | 0 | 16 | 2021–2026 |
| 914 | PROVIGATE | 17 | 00% | 0 | 17 | 2022–2026 |
| 915 | QUANTUM SURGICAL | 17 | 317.6% | 0 | 14 | 2021–2026 |
| 916 | REIFENH USER KG MASCHINENFABRIK | 17 | 15.9% | 1 | 15 | 2020–2025 |
| 917 | RIETER AUTOMATIC WINDER | 17 | 635.3% | 0 | 11 | 2022–2025 |
| 918 | SAGE ELECTROCHROMICS | 17 | 423.5% | 8 | 5 | 2022–2025 |
| 919 | SANDVIK SRP | 17 | 423.5% | 4 | 9 | 2022–2025 |
| 920 | SHANGHAI UNITED IMAGING HEALTHCARE | 17 | 00% | 0 | 17 | 2022–2025 |
| 921 | SYNTEGON TECHNOLOGY | 17 | 15.9% | 0 | 16 | 2022–2026 |
| 922 | TATA STEEL NEDERLAND TECHNOLOGY | 17 | 211.8% | 1 | 14 | 2022–2026 |
| 923 | TBM | 17 | 1058.8% | 2 | 5 | 2022–2025 |
| 924 | TERUMO | 17 | 15.9% | 1 | 15 | 2022–2026 |
| 925 | TYCO ELECTRONICS SHANGHAI | 17 | 00% | 0 | 17 | 2022–2025 |
| 926 | UNIMATEC | 17 | 1164.7% | 0 | 6 | 2022–2025 |
| 927 | ARIANEGROUP | 16 | 00% | 0 | 16 | 2023–2026 |
| 928 | ARKA ENERGY | 16 | 00% | 2 | 14 | 2022–2023 |
| 929 | ARXADA | 16 | 00% | 3 | 13 | 2022–2026 |
| 930 | B HLER FOOD EQUIPMENT | 16 | 318.8% | 1 | 12 | 2022–2024 |
| 931 | BEAM THERAPEUTICS | 16 | 00% | 0 | 16 | 2022–2026 |
| 932 | BIOMARIN PHARMACEUTICAL | 16 | 00% | 0 | 16 | 2022–2026 |
| 933 | BIRLA CARBON U | 16 | 00% | 0 | 16 | 2022–2026 |
| 934 | BODITECH MED | 16 | 425% | 0 | 12 | 2022–2025 |
| 935 | C4 THERAPEUTICS | 16 | 16.3% | 2 | 13 | 2021–2026 |
| 936 | CREDENCE MEDSYSTEMS | 16 | 00% | 1 | 15 | 2022–2026 |
| 937 | CYTEC INDUSTRIES | 16 | 212.5% | 2 | 12 | 2022–2026 |
| 938 | EVE POWER | 16 | 00% | 0 | 16 | 2023–2026 |
| 939 | FACC | 16 | 212.5% | 0 | 14 | 2022–2025 |
| 940 | FLOWSERVE | 16 | 16.3% | 0 | 15 | 2022–2025 |
| 941 | FOSBER | 16 | 531.3% | 0 | 11 | 2020–2025 |
| 942 | GEBERIT INTERNATIONAL | 16 | 00% | 0 | 16 | 2022–2026 |
| 943 | GOLDWIND SCIENCE TECHNOLOGY | 16 | 531.3% | 0 | 11 | 2022–2025 |
| 944 | GROZ BECKERT KG | 16 | 00% | 0 | 16 | 2022–2026 |
| 945 | GS YUASA INTERNATIONAL | 16 | 425% | 1 | 11 | 2022–2026 |
| 946 | INSILICO MEDICINE IP | 16 | 00% | 0 | 16 | 2023–2026 |
| 947 | INTELLIA THERAPEUTICS | 16 | 16.3% | 2 | 13 | 2018–2025 |
| 948 | IPG PHOTONICS | 16 | 00% | 0 | 16 | 2022–2026 |
| 949 | KANEKA | 16 | 212.5% | 0 | 14 | 2022–2025 |
| 950 | KLEEMANN | 16 | 425% | 0 | 12 | 2020–2025 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →